Inhibition of a lncRNA for treatment of melanoma

US9821004B2 · kind B2 · utility

Assignees

• VIB VZW · BE
• Katholieke Universiteit Leuven, KU LEUVEN R&D · BE
• UNIVERSITEIT GENT · BE

Inventors

• Jean-Christophe Marine · Brussels, BE
• Eleonora Leucci · Linden, BE
• Joke Vandesompele · Zwijnaarde, BE
• Pieter Mestdagh · Brugge, BE

Key dates

• Filing date: Aug 20, 2014
• Grant date: Nov 21, 2017
• Expiry date: Aug 20, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/158
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This disclosure relates to the field of cancer, particularly the field of melanoma. It was found that a particular long non-coding RNA (lncRNA) is specifically up-regulated in melanoma (but not other tumor) cells as compared to melanocytes. Inhibition of this lncRNA in melanoma cells leads to induction of apoptosis and is a novel therapeutic strategy in the treatment of melanoma.